Scientists at the Institute for Problems of Chemical and Energetic Technologies (IPCET), SB RAS (Biysk), with the participation of TSU colleagues, have developed tiovyurtsin – a generic drug for the treatment of pain of various etiology. A feature of the new analgesic is having none of the side effects typical of steroid and non-steroidal anti-inflammatory drugs.
- As a raw material for the new drug we used glyoxal – a substance for which the industrial technology of synthesis was developed by chemists at Tomsk State University, - said Sergey Sysolyatin, the director of the IPCET SB RAS (a graduate of TSU’s Faculty of Chemistry). - High-energy compounds are also based on glyoxal. At the intermediate stage of synthesis, we are withdrawing a small portion of the substance, modifying it, and then obtaining a drug with excellent pharmacological characteristics.
Preclinical tests carried out at the ED Goldberg Research Institute of Pharmacology and Regenerative Medicine (Tomsk) showed that the new analgesic suppresses pain syndromes of various etiology and has a longer period of effectiveness than other painkillers, but has no toxic effects on the body. According to experts, tiovyurtsin is in the IV class of danger - low-hazard substances. The extent of its toxic effects on the body by gravity is only comparable to overeating.
Furthermore, in the case of prolonged use of the drug (28 days), drug dependence has not developed, the breath does not suffer, and there is no stimulating effect on the central nervous system, which indicates the absence of the effects observed in the use of morphine.
- I think that new technology of the Biysk Institute is a big step forward for modern pharmacology, - says Alexander Vorozhtsov, a professor at TSU, deputy director of the IPCET SB RAS, and director of the technological platform Medicine of the Future. - Previously, the use of glyoxal as a raw material for the synthesis of hexaazaisowurtzitane has had a primarily defense application. Only in recent years these chemicals began to be considered for application in medicine.
This issue is discussed in the scientific and medical literature, but the priority publications on the subject and now the practical experience with it have been only by Russian scientists.
Preclinical tests of the new drug are in the final stage. This development already has a patent, and this joint project of Biysk and Tomsk scientists is planned to be implemented in the Federal Program Development of the Pharmaceutical and Medical Industry of the Russian Federation for the Period to 2020 and Beyond.
Key research areas of the IPCET SB RAS are the synthesis of high-energy compounds, drugs, and biologically active substances, the creation of new materials, and the study of the processes of combustion and explosion.